Annals of Oncology 12:311-319, 2001
© 2001 European Society for Medical Oncology
research-article |
Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH
1Department of Pediatric Hematology and Oncology, University of Heidelberg Heidelberg
2Department of Pediatric Pathology, University of Kiel Cediff, UK
3Department of Pathology, University of Wales College of Medicine Cardiff, UK
4Department of Pediatric Radiology, University of Heidelberg Heidelberg
5Institute of Biostatistics, University of Heidelberg Heidelberg
6Pediatric Hematology and Oncology, University of Saarland Homburg/Saar, Germany
7Department of Pediatric Hematology and Oncology, AMC Amsterdam, The Netherlands
Correspondence to:A. Weirich, MD, Abteilung Hämatologie und Onkologie Universitätskinderklinik, Im Neuenheimer Feld 150, 69120 Heidelberg, Germany, E-mail: angela_weirich{at}med.uni-heidelberg.de
Background: Histologic subtypes of standard histology Wilms' tumor (WT) and the effect of preoperative therapy on their clinical and histologic features, deserve to be analysed in respect to outcome to find an adequate baseline for therapy.
Patients and methods: The German Society of Paediatric Oncology & Haematology enrolled patients from January 1989 to March 1994 for therapy according the International Society of Paediatric Oncology trial & study 9. Standardised preoperative therapy with dactinomycin and vincristine for 4–8 weeks was generally applied in patients between 0.5 and 16 years with localized renal tumors and imaging typical for WT. In 99.5% of cases representative material was sent for review to the Kiel Paediatric Tumour Registry. For prospective subtyping of 329 WT (258 after preoperative therapy, 71 with immediate surgery) modified Beckwith & Palmer criteria were used. Reduction in volume measured by imaging prior to chemotherapy and surgery was used to assess response (poor response: reduction <40%; good response: reduction >40%).
Results: There were 39% of patients treated with immediate surgery and 12.4% of patients with preoperative therapy in the age group up to 12 months. The difference in age (P = 0.022) was linked with different amounts of epithelial WT (15.5% vs. 3.1%), median age: 0.58 and 0.93 years. Due to the effect of chemotherapy the amount of other WT changed: stromal 0% to 14%, mixed 45.1% to 29.4%, blastemal 39.4% to 9.3%). After preoperative therapy 37.6% of WT were predominantly regressive, 6.6% completely necrotic. Poor response was frequent in differentiated WT (86% of stromal, 75% of epithelial WT) but none relapsed. In the other WT with viable tumor left after preoperative therapy > 70% had good response, poor response was a risk factor (P = 0.0057).
Conclusions: Subtyping according modified Beckwith & Palmer can be used in WT after preoperative therapy to stratify postoperative therapy in future. A milder therapy could be tested in differentiated WT at low stages and an intensified in the others with viable tumor left and poor response, i.e., mainly blastemal WT.
clinical response, histologic subtype, nephro-blastoma, preoperative chemotherapy, prognostic factor, risk of relapse
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Vuononvirta, N. J. Sebire, B. Messahel, N. Perusinghe, J. S. Reis-Filho, K. Pritchard-Jones, G. M. Vujanic, and C. Jones Expression of Hepatocyte Growth Factor and Its Receptor Met in Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development Clin. Cancer Res., April 15, 2009; 15(8): 2723 - 2730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Natrajan, J. S. Reis-Filho, S. E. Little, B. Messahel, M.-A. Brundler, J. S. Dome, P. E. Grundy, G. M. Vujanic, K. Pritchard-Jones, and C. Jones Blastemal Expression of Type I Insulin-Like Growth Factor Receptor in Wilms' Tumors Is Driven by Increased Copy Number and Correlates with Relapse Cancer Res., December 1, 2006; 66(23): 11148 - 11155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Metzger and J. S. Dome Current Therapy for Wilms' Tumor Oncologist, November 1, 2005; 10(10): 815 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Schlomm, B. Gunawan, H.-J. Schulten, B. Sander, K. Thangavelu, N. Graf, I. Leuschner, R.-H. Ringert, and L. Fuzesi Effects of Chemotherapy on the Cytogenetic Constitution of Wilms' Tumor Clin. Cancer Res., June 15, 2005; 11(12): 4382 - 4387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Green In Reply: J. Clin. Oncol., May 1, 2005; 23(13): 3157 - 3158. [Full Text] [PDF]
|
|
|
|
|
|
C. Jones, K. Pritchard-Jones, M. A. Ghanem, T. H. Van der Kwast, R. M. Nijman, and G. J. van Steenbrugge MIB-1 and p27Kip1 Expression in Nephroblastoma Clin. Cancer Res., November 15, 2004; 10(22): 7785 - 7786. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Weirich, R. Ludwig, N. Graf, U. Abel, I. Leuschner, G. M. Vujanic, O. Mehls, J. Boos, J. Beck, B. Royer-Pokora, et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity Ann. Onc., May 1, 2004; 15(5): 808 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Schumacher, S. Schuhen, S. Sonner, A. Weirich, I. Leuschner, D. Harms, J. Licht, S. Roberts, and B. Royer-Pokora Two Molecular Subgroups of Wilms' Tumors with or without WT1 Mutations Clin. Cancer Res., June 1, 2003; 9(6): 2005 - 2014. [Abstract] [Full Text] [PDF]
|
|